Trending

#atra

Latest posts tagged with #atra on Bluesky

Latest Top
Trending

Posts tagged #atra

Preview
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel Atara Biotherapeutics (Nasdaq: ATRA) said a Type A meeting with FDA has been scheduled to discuss the Complete Response Letter for the tabelecleucel (tab-cel) Biologics License Application held by partner Pierre Fabre Pharmaceuticals. Pierre Fabre, with Atara support, will seek to address CRL points and enable a BLA resubmission using additional efficacy data collected since the original submission. Atara expects to provide a further regulatory update in the second quarter.

#ATRA Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

www.stocktitan.net/news/ATRA/atara-biothera...

0 0 0 0
Post image

Mexican Design Studio ATRA FORM Frames its New York Outpost as a Multisensorial Experience The multivalent practice stages its new Hudson Square gallery as a temple-like oasis, replete with biohack...

#Art #Main #ATRA #ATRA #FORM #biohacking #furniture #home […]

[Original post on design-milk.com]

3 0 0 0
Preview
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel Atara Biotherapeutics (NASDAQ: ATRA) said partner Pierre Fabre Pharmaceuticals submitted a request for a Type A meeting with the FDA on March 3, 2026 to address the Complete Response Letter dated January 9, 2026 for tabelecleucel (tab-cel).The briefing book reportedly argues the ALLELE study was adequate and includes updated longer-term ALLELE efficacy data, additional supportive development data, and post-marketing data from Europe intended for a potential resubmission.

#ATRA Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

www.stocktitan.net/news/ATRA/atara-biothera...

0 0 0 0
Post image Post image

アバター 伝説の少年アンの漫画です
avatar last airbender comic

#AvatarTheLastAirbender
#atra

3 0 0 0
Preview
Pomerantz Law Firm Launches Investigation into Atara Biotherapeutics for Potential Investor Claims Pomerantz Law Firm is investigating Atara Biotherapeutics for possible securities fraud following a major stock drop due to FDA issues. Investors should contact the firm for inquiries.

Pomerantz Law Firm Launches Investigation into Atara Biotherapeutics for Potential Investor Claims #United_States #New_York #Pomerantz #Atara_Biotherapeutics #ATRA

0 0 0 0
Post image

Classic Matchup

Yep, Atra is bad with the dice... the problem is if she just loses on purpose or she's genuinely naive :V
Winner: FuryFire



#DarkShadow777Art #bondage #tentacles #demon #nudity #sizedifference #shortstack #mousegirl #MyOCs #Atra #FuryFire #furry

11 3 0 0
MultiSearch Tag Explorer MultiSearch Tag Explorer - Explore tags and search results by aéPiot

#OZI #VOICE OF #THE #FOREST
headlines-world.com/advanced-sea...
#GYNATOMA #ATRA
multi-search-tag-explorer.allgraph.ro/advanced-sea...
MultiSearch Tag Explorer

allgraph.ro

0 0 0 0
Post image Post image Post image Post image

Folks in Poughkeepsie have plans to join the nationwide force of Saturday rallies. i came across the group on the way home from a slightly more established crew up the river. #ATRA will be downtown from 1 to 3. More voices, louder voices always welcome. #hudsonvalleyresists #poughkeepsie

0 0 0 0
Preview
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress Atara Biotherapeutics (Nasdaq: ATRA) reported Q3 2025 results and operational updates. The FDA accepted the BLA for tabelecleucel (tab-cel/Ebvallo) with Priority Review and a PDUFA target action date of January 10, 2026. Atara completed transfer of substantially all tab-cel activities and BLA sponsorship to Pierre Fabre, which would trigger a $40 million milestone payment upon FDA approval. Cash, cash equivalents and short-term investments were $13.7M as of September 30, 2025. Q3 net loss was $4.3M ($0.32/sh) versus $21.9M a year earlier; total revenues were $3.5M versus $40.2M in Q3 2024. Workforce reduced by ~29%, retaining ~15 employees.

#ATRA Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

www.stocktitan.net/news/ATRA/atara-biothera...

0 0 0 0
Post image Post image Post image

Il n'y a pas que la DGA qui a recours à des Avions Banc d'Essais génériques.

Son pendant allemand, le #DLR @dlr-en.bsky.social est en train de qualifier son #A320 #ATRA (Advanced Technology Research Aircraft) dont une 1ère mission consistera en des tests du radar AESA Mk1 de l'Erofighter.

3 0 1 0
Leading Indicators, Tuesday September 23, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Tue Sept 23rd - #SAVA #PDYN #NUTX #IMTX #GSIT #FAT #EM #CYCN #BHST #ATRA #VEL #SPI - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0
Preview
Atara's Tab-cel Gets FDA Priority Review: $40M Milestone Payment at Stake as January PDUFA Date Approaches Atara secures FDA Priority Review for tab-cel PTLD therapy with January 2026 decision date. 60% reduction in operating costs achieved. See milestone details.

#ATRA Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

www.stocktitan.net/news/ATRA/atara-biothera...

0 0 0 0
Preview
Atara Biotherapeutics’ Tab-cel® Receives FDA Priority Review for EBV+ Post-Transplant Lymphoproliferative Disease Atara Biotherapeutics (Nasdaq: ATRA) announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for tabelecleucel (tab-

Nasdaq: #ATRA
#Atarabiotherapeutics’ tab-cel has received FDA Priority Review for EBV+ PTLD, a rare post-transplant cancer. A decision is expected by Jan 15, 2025—potentially making it the first approved therapy for this life-threatening disease.
prismmarketview.com/atara-biothe...

0 0 0 0
Preview
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical program. Atara Biotherapeutics resubmitted the tabelecleucel Biologics License Application to the U.S. Food and Drug Administration on July 11. SECAUCUS, N.J., July 15, 2025/ PRNewswire/-- Pierre Fabre Pharmaceuticals, Inc. today announced...

#ATRA Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

www.stocktitan.net/news/ATRA/perre-fabre-ph...

0 0 0 0
Preview
Atara's Breakthrough EBV+ PTLD Therapy Returns to FDA Review: $40M Payment at Stake Novel T-cell therapy shows 48.8% response rate in treating rare post-transplant disease. First-in-class treatment aims to address critical unmet need. See trial data.

#ATRA Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

www.stocktitan.net/news/ATRA/atara-biothera...

0 0 0 0
Post image

Iraq, But Funny lives up to its title Iraq, But Funny , through 7/20 at Lookingglass Theatre The post <i>Iraq, But Funny</i> lives up to its title appeared first on Chicago Reader .

#Performing #Arts #Theater #Theater #Review #Atra #Asdou #Dalia #Ashurina #Iraq #But

Origin | Interest | Match

0 0 0 0
Post image

Iraq, But Funny lives up to its title Iraq, But Funny , through 7/20 at Lookingglass Theatre The post <i>Iraq, But Funny</i> lives up to its title appeared first on Chicago Reader .

#Performing #Arts #Theater #Theater #Review #Atra #Asdou #Dalia #Ashurina #Iraq #But

Origin | Interest | Match

0 0 0 0

#longform #atra

Preorders for this are open now! Amazon won't let us do it with Draft2Digital and paperback version preorders will be coming later, but if you wanna pick up a copy:

9 4 0 0
Preview
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress Atara Biotherapeutics (ATRA) reported Q1 2025 financial results and operational updates. The company reported net income of $38.0 million ($3.53 basic EPS), compared to a net loss of $31.8M in Q1 2024. Total revenues increased to $98.1 million, up from $27.4M YoY. Atara has transferred all manufacturing responsibilities of tabelecleucel to Pierre Fabre Laboratories and implemented significant cost-cutting measures, including an 85% workforce reduction since December 2024. The company secured $16 million in new financing through a stock and warrant offering. The FDA has lifted clinical holds on EBVALLO™ studies and granted a Type A meeting in Q2 2025 to discuss the Complete Response Letter issues. Atara expects to reduce operating expenses by 65% in 2025 and projects its cash runway to extend into Q1 2026.

#ATRA Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

www.stocktitan.net/news/ATRA/atara-biothera...

0 0 0 0
Preview
Atara Secures $16M Backing from Top Biotech Investors to Advance Critical BLA Approval Fresh capital from EcoR1, Redmile backs Atara's tab-cel BLA approval pursuit. Key institutional investors show confidence in T-cell therapy platform. Learn more.

#ATRA Atara Biotherapeutics Announces Pricing of $16 Million Offering

www.stocktitan.net/news/ATRA/atara-biothera...

0 0 0 0
Tropes for the anthology and the cover. The cover is a woman laying on her back with a rose on her chest that reads:
a sapphic erotic monster romance anthology
A Thorn's Rose
featuring stories by 10 authors
curated by Dae Storm

Around the cover teaser is a bunch of tropes:
"Sapphic AF, 5-10k words each"
"dominant dragoness"
"bi/pan rep"
"trans rep"
"woods and werewolves"
"mating mermaids"
"neurodivergent rep"
"smarmy panther shifter t-girl" (I wrote this one!)
"balcony seggs"
"headless horsewoman gives head"
"tiny houses and mouthwomen"

Tropes for the anthology and the cover. The cover is a woman laying on her back with a rose on her chest that reads: a sapphic erotic monster romance anthology A Thorn's Rose featuring stories by 10 authors curated by Dae Storm Around the cover teaser is a bunch of tropes: "Sapphic AF, 5-10k words each" "dominant dragoness" "bi/pan rep" "trans rep" "woods and werewolves" "mating mermaids" "neurodivergent rep" "smarmy panther shifter t-girl" (I wrote this one!) "balcony seggs" "headless horsewoman gives head" "tiny houses and mouthwomen"

A synopsis of my work!

(Un)Familiar by Holly Adder

Lillian Tremaine has been obsessed with familiars since she was a child. The idea of a lifelong relationship fascinates her, but she never found one of her own. Instead, she turned to writing about them. 

When she's interrupted during a reading of her book at an occult bookstore by a woman whose eyes shine like a panther in the night, though, she starts to wonder whether the connection she craves could be found elsewhere.

And they fuck nasty and bloody in the back seat of the shifter’s car while insulting each other, btw.

A synopsis of my work! (Un)Familiar by Holly Adder Lillian Tremaine has been obsessed with familiars since she was a child. The idea of a lifelong relationship fascinates her, but she never found one of her own. Instead, she turned to writing about them. When she's interrupted during a reading of her book at an occult bookstore by a woman whose eyes shine like a panther in the night, though, she starts to wonder whether the connection she craves could be found elsewhere. And they fuck nasty and bloody in the back seat of the shifter’s car while insulting each other, btw.

A list of tropes from my work.
"Lesbian girlfaggots"
"barbed cat girl dick that makes you feel like you're getting pregnant"
"nasty car sex"
"smarmy bitch/icy academic"
"horny banter"
"annoying bitch eating raw meat in public"
"T4T girldick obsession"
"magic weed"
"embarrassingly horny nerd"
"it's not a good fuck unless someone needs stitches after"

A list of tropes from my work. "Lesbian girlfaggots" "barbed cat girl dick that makes you feel like you're getting pregnant" "nasty car sex" "smarmy bitch/icy academic" "horny banter" "annoying bitch eating raw meat in public" "T4T girldick obsession" "magic weed" "embarrassingly horny nerd" "it's not a good fuck unless someone needs stitches after"

Quotes from my story!
"Yeah, fuck it, why not."
"I *knew* you were my kind of freak."
"Do you always listen to waht dangerous woman you've just met tell you to do?"
"Sometimes I'm prone to making bad decisions."
"I see. What's the over-under on you making a few more of those bad decisions?"

Quotes from my story! "Yeah, fuck it, why not." "I *knew* you were my kind of freak." "Do you always listen to waht dangerous woman you've just met tell you to do?" "Sometimes I'm prone to making bad decisions." "I see. What's the over-under on you making a few more of those bad decisions?"

#longform #atra

Hey gang! I'm super excited to announce I'll be getting published in an anthology sometime in the next few months! Preorder link will be coming soon.

My work is called (Un)Familiar and it's a monsterfucker anthology curated by the lovely @ddanddauthor.bsky.social!

26 13 5 2
An infographic for the anthology: a reddish background with a white lineart rose in the middle, dividing the anthology information on the left from the story information on the right. 

The left reads:
"A Thorn's Rose
A sapphic erotic monster romance anthology
10 erotic romance stories from 5k-10k words by 10 different authors"
The cover is included, showing the title and a photograph of a rose tucked into underwear and held tight to someone's skin.
The bottom reads "Preorder coming soon"

The right reads:
"My story
To a Flame
Jen is a young closeted lesbian who recently moved away from home to attend college. She can only afford a weird old house, and things take a turn for the even weirder when she finds a visitor stopping by. A large, compound-eyed, six-legged, winged visitor. Maybe, though, a giant moth can be a friend.
Maybe even more..."
The bottom reads: "@jrade-writes.bsky.social"

An infographic for the anthology: a reddish background with a white lineart rose in the middle, dividing the anthology information on the left from the story information on the right. The left reads: "A Thorn's Rose A sapphic erotic monster romance anthology 10 erotic romance stories from 5k-10k words by 10 different authors" The cover is included, showing the title and a photograph of a rose tucked into underwear and held tight to someone's skin. The bottom reads "Preorder coming soon" The right reads: "My story To a Flame Jen is a young closeted lesbian who recently moved away from home to attend college. She can only afford a weird old house, and things take a turn for the even weirder when she finds a visitor stopping by. A large, compound-eyed, six-legged, winged visitor. Maybe, though, a giant moth can be a friend. Maybe even more..." The bottom reads: "@jrade-writes.bsky.social"

Excited to announce my short story, to be published in an anthology by @ddanddauthor.bsky.social - "A Thorn's Rose."

"To a Flame" is mine; 10k words.

It's a sort of queer coming-of-age type story, but with a giant moth lady.

Stay tuned for more!
<3
#ATRA #LGBTQ 💙📚 #writesky #monsters #romance

10 4 1 2
Preview
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) Atara Biotherapeutics (NASDAQ: ATRA) announced that the FDA has lifted the clinical hold on its EBVALLO™ (tabelecleucel) program, which was imposed in January 2025 due to GMP compliance issues at a third-party manufacturing facility. The company can now resume its Phase 3 ALLELE study for EBV+ PTLD patients and Phase 2 label-expansion study. Additionally, the FDA has granted a Type A meeting to discuss addressing issues from the January 2025 Complete Response Letter (CRL) and the path forward for BLA resubmission. Atara has temporarily paused its strategic options evaluation process, which includes potential acquisition, merger, or sale considerations, pending clarity on the BLA resubmission timeline.

#ATRA Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

www.stocktitan.net/news/ATRA/atara-biothera...

0 0 0 0
Preview
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress Atara Biotherapeutics (NASDAQ: ATRA) reported its Q4 and full year 2024 financial results, facing significant operational changes. The company received a Complete Response Letter (CRL) from FDA for EBVALLO in January 2025, leading to a clinical hold due to third-party manufacturing facility issues.Key financial metrics include: Q4 2024 net loss of $12.7 million ($1.19 per share)Full year 2024 net loss of $85.4 million ($11.41 per share)Cash position of $42.5 million as of December 31, 2024The company implemented a 50% workforce reduction and paused its CAR-T programs (ATA3219 and ATA3431) to preserve resources. Atara secured potential funding of up to $15 million through an equity line of credit with Redmile Group and is exploring strategic alternatives including potential merger or acquisition options.

#ATRA Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

www.stocktitan.net/news/ATRA/atara-biothera...

0 0 0 0
Preview
Pomerantz Law Firm Launches Investigation into Atara Biotherapeutics for Alleged Securities Violations The Pomerantz Law Firm is investigating potential securities fraud involving Atara Biotherapeutics. Investors are encouraged to join the inquiry.

Pomerantz Law Firm Launches Investigation into Atara Biotherapeutics for Alleged Securities Violations #United_States #New_York #Pomerantz_Law_Firm #Atara_Biotherapeutics #ATRA

0 0 0 0
Preview
Pomerantz Law Firm Launches Investigation Into Atara Biotherapeutics' Securities Practices Pomerantz LLP is investigating potential securities fraud claims against Atara Biotherapeutics, following significant stock price drops after FDA news.

Pomerantz Law Firm Launches Investigation Into Atara Biotherapeutics' Securities Practices #United_States #New_York #Pomerantz_Law_Firm #Atara_Biotherapeutics #ATRA

0 0 0 0